China's State Food and Drug Administration (SFDA) is clamping down on its drug contract manufacturing companies. The SFDA aims to prevent the export of counterfeit products.
Sidley
Thursday, 25 August 2011
New rules for Chinese contract manufacturers
Wednesday, 24 August 2011
Contract manufacturing to double in next 10 years
Business information provider Visiongain predicts that global contract manufacturing revenues will double from 2011 to 2021. The company says revenues will reach $64.07bn in 2016 - with a CAGR of 8.7% between 2010 and 2016 - driven by manufacturing of finished dosage forms.
Pharma Times
Monday, 22 August 2011
BI plant to exit contract manufacturing
Boehringer Ingelheim's Ben Venue laboratories facility in Ohio is to cease contract manufacturing activities and focus on generics operations. Contract manufacturing work will be transitioned to other Boehringer plants over the next few years.
Nasdaq
Monday, 15 August 2011
Congress to pass plant inspection law
The US Congress is expected to pass new legislation that will enable the FDA to inspect overseas generic drug manufacturing facilities every two years. Generic drug manufacturers will pay fees totalling $299m/year to fund the inspections in return for speedier approval of products.
New York Times
Fine chemicals revenues rise at Ampac
Revenues at Ampac Fine Chemicals rose 55% to $30.8m in its Q3 2011 compared to 2010. The company attributed this to increases in revenues from core products in its key therapeutic areas including a 139% rise in revenues from anti-viral products.
Seeking Alpha
Onyx acquired by Ipca Laboratories
Onyx Scientific has been acquired by Ipca Laboratories for £4.6m. The UK-based business will be operated as part of Ipca's Covenance custom manufacturing business unit.
North East Business
Thursday, 11 August 2011
Wednesday, 10 August 2011
Tuesday, 9 August 2011
AMRI Q2 revenues rise
AMRI reported that Q2 2011 revenues for its development/small scale contract manufacturing rose 18% to $9.1m and for its large scale contract manufacturing rose 21% to $25.5m over 2010.
Albany Business Review
Roche Colorado acquired
ICIG is to acquire Roche Colorado and its Boulder, CO, manufacturing facility for an undisclosed fee. ICIG will operate the business as part of its Corden Pharma unit and rebrand the facility as Corden Pharma Colorado. The facility will continue to supply Roche with a number of APIs.
In-pharma Technologist
Joint inspection programme reports
The EMA, the FDA and Australia's Therapeutic Goods Administration have concluded their joint inspection pilot programme. During the two pilots the agencies exchanged more than 250 documents relating to 54 different medicines and organised 13 collaborative inspections of clinical trials. As a result, the agencies will continue with their collaboration on inspections and build on the lessons learned during the pilot phases.
Wall Street Journal
Monday, 8 August 2011
DSM seeks CMO partner in Asia
DSM is seeking a partner in Asia for its pharmaceutical products custom manufacturing unit. The company is looking to serve new clients in Asia and smaller customers to reduce its reliance on its current large pharma customer base.
Outsourcing Pharma
Tuesday, 2 August 2011
DSM pharma sales slow
DSM reported that sales for its pharma-facing business unit fell to €178m in Q2 2011 from €195m in the same period in 2010 and H1 sales fell to €341m from €381m. The company said that its pharma sales and results improved compared to Q1, but it is conscious that overall performance of the cluster remains below acceptable levels. DSM attributed the lower Q2 sales to the weaker US dollar and lower volumes at DSM Pharmaceutical Products.
DSM
Subscribe to:
Posts (Atom)
